Lead
Insulet, a leading medical device company, has enrolled the first participant in a pivotal study for a fully closed loop automated insulin delivery system, aimed at individuals with Type 2 diabetes. This marks a significant step towards Insulet’s first fully automated device for insulin delivery, which could revolutionize diabetes management.
Details
The study, known as EVOLVE, will assess the safety and efficacy of the system, which is designed to automatically adjust insulin delivery based on continuous glucose monitoring. The pivotal trial is expected to involve a substantial number of participants and is a critical phase in bringing this innovative technology to market.
Company Background
Insulet, founded in 2000 and based in the United States, specializes in the development of tubeless patch pumps for insulin delivery. Their flagship product, the Omnipod, has been a game-changer in the diabetes management space, providing users with a more convenient and less invasive option for insulin administration.
Market Context
This development is particularly significant as it addresses a growing need for advanced diabetes management solutions. The fully closed loop system represents a leap forward in automating insulin delivery, potentially reducing the burden on patients and improving glycemic control. It also signifies a competitive move in the medtech industry, where innovation in diabetes care is a top priority.
If you are exploring product design and medical device engineering, BangDesign has relevant experience.
Source: MedTech Dive